Skip to main content
. Author manuscript; available in PMC: 2013 Oct 1.
Published in final edited form as: Thorax. 2013 Jan 3;68(4):372–379. doi: 10.1136/thoraxjnl-2012-202556

Table 4.

Relationship between maternal pre-pregnancy fat mass (kg) and exhaled nitric oxide and lung function in the offspring at age 6 years

Unadjusted analysis Model 1 Model 2
Beta (95% CI) P-value n Beta (95% CI) P-value n Beta (95% CI) P-value n
FEV1 z-score 0.0349 (−0.0413, 0.1111) 0.37 793 0.0274 (−0.0476, 0.1025) 0.47 793 0.0230 (−0.0555, 0.1015) 0.56 784
FVC z-score 0.0433 (−0.0439, 0.1306) 0.33 793 0.0301 (−0.0586, 0.1188) 0.5 765 0.0301 (−0.0586, 0.1188) 0.5 765
FEF25-75% z-score 0.0163 (−0.0796, 0.1122) 0.74 793 0.0181 (−0.0775, 0.1137) 0.71 793 0.0071 (−0.0886, 0.1028) 0.88 793
FEV1/FVC z-score −0.0190 (−0.1043, 0.0663) 0.66 793 −0.0130 (−0.0998, 0.0739) 0.77 765 −0.0130 (−0.0998, 0.0739) 0.77 765
Exhaled nitric oxide −0.0575 (−0.1667, 0.0517) 0.30 482 −0.0908 (−0.2018, 0.0203) 0.11 477 −0.0908 (−0.2018, 0.0203) 0.11 477
Model 3 Model 4
Beta (95% CI) P-value n Beta (95% CI) P-value n
FEV1 z-score 0.0115 (−0.0702, 0.0932) 0.78 721 0.0122 (−0.0684, 0.0928) 0.76 784
FVC z-score 0.0287 (−0.0625, 0.1199) 0.54 713 0.0001 (−0.0913, 0.0916) 0.99 765
FEF25-75% z-score −0.0035 (−0.1031, 0.0961) 0.94 725 0.0160 (−0.0829, 0.1149) 0.75 793
FEV1/FVC z-score −0.0293 (−0.1181, 0.0594) 0.51 713 0.0055 (−0.0846, 0.0956) 0.9 765
Exhaled nitric oxide −0.0989 (−0.2152, 0.0174) 0.09 434 −0.0889 (−0.2029, 0.0250) 0.12 477

Regression coefficient represents change in outcome per 10 kg of maternal pre-pregnancy fat mass.

Model 1 Adjusted for potential confounders significantly associated with the outcome, excluding child’s birthweight and gestation.

FEV1-child’s gender; FVC-maternal smoking in pregnancy and rhinitis, and child’s gender; FEF25-75%-maternal parity and child’s gender; FEV1/FVC-maternal rhinitis, eczema, smoking in pregnancy and parity; eNO-maternal height, asthma and eczema.

Model 2 adjusted for potential confounders significantly associated with the outcome, including child’s birthweight and gestation.

FEV1-maternal height, and child’s gender and birthweight; FVC-maternal smoking in pregnancy and rhinitis, and child’s gender; FEF25-75%-maternal parity and child’s gender and gestation; FEV1/FVC-maternal rhinitis, eczema, smoking in pregnancy and parity; eNO-maternal height, asthma and eczema.

Model 3 adjusted for increase in adiposity between birth and 6 months and potential confounders significantly associated with the outcome including child’s birthweight and gestation (listed in Model 2).

Model 4 adjusted for child’s BMI at age 6 years and potential confounders significantly associated with the outcome including child’s birthweight and gestation (listed in Model 2).